40.16
0.32%
-0.13
プレマーケット:
40.90
0.74
+1.84%
前日終値:
$40.29
開ける:
$40.5
24時間の取引高:
1.71M
Relative Volume:
1.08
時価総額:
$7.42B
収益:
$29.52M
当期純損益:
$-567.06M
株価収益率:
-10.97
EPS:
-3.66
ネットキャッシュフロー:
$-551.11M
1週間 パフォーマンス:
+0.83%
1か月 パフォーマンス:
-8.85%
6か月 パフォーマンス:
-12.96%
1年 パフォーマンス:
+49.13%
Revolution Medicines Inc Stock (RVMD) Company Profile
名前
Revolution Medicines Inc
セクター
電話
415-766-3638
住所
700 SAGINAW DR, REDWOOD CITY, CA
RVMD を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
40.16 | 7.42B | 29.52M | -567.06M | -551.11M | -3.66 |
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-07-16 | 繰り返されました | Needham | Buy |
2024-07-12 | 開始されました | Barclays | Overweight |
2024-07-08 | 開始されました | Jefferies | Buy |
2024-04-12 | 繰り返されました | Needham | Buy |
2024-04-10 | アップグレード | Raymond James | Outperform → Strong Buy |
2024-03-11 | 開始されました | Piper Sandler | Overweight |
2024-01-05 | アップグレード | BofA Securities | Neutral → Buy |
2024-01-04 | 開始されました | Wedbush | Outperform |
2023-11-16 | 開始されました | Raymond James | Outperform |
2023-02-28 | アップグレード | JP Morgan | Neutral → Overweight |
2022-12-14 | 開始されました | Needham | Buy |
2022-10-21 | 開始されました | Oppenheimer | Outperform |
2022-05-20 | 開始されました | BofA Securities | Neutral |
2022-03-01 | アップグレード | Stifel | Hold → Buy |
2021-09-23 | 開始されました | Stifel | Hold |
2021-08-12 | ダウングレード | Goldman | Buy → Neutral |
2021-05-18 | 開始されました | Goldman | Buy |
2020-05-21 | 開始されました | H.C. Wainwright | Buy |
2020-03-09 | 開始されました | Cowen | Outperform |
2020-03-09 | 開始されました | Guggenheim | Buy |
2020-03-09 | 開始されました | JP Morgan | Neutral |
すべてを表示
Revolution Medicines Inc (RVMD) 最新ニュース
Sandy Cove Advisors LLC Acquires Shares of 42,008 Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Down -7.83% in 4 Weeks, Here's Why Revolution Medicines (RVMD) Looks Ripe for a Turnaround - MSN
Is Revolution Medicines, Inc. (RVMD) the Best Russell 2000 Stock to Invest in According to Analysts? - Insider Monkey
Revolution Medicines' SWOT analysis: stock poised for growth amid clinical trials - MSN
Certain Restricted Stock Units of Revolution Medicines, Inc. are subject to a Lock-Up Agreement Ending on 18-JAN-2025. - Marketscreener.com
Revolution Medicines (RVMD) Loses -7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Revolution Medicines (NASDAQ:RVMD) Trading Down 4.6%Should You Sell? - MarketBeat
(RVMD) Trading Advice - Stock Traders Daily
Revolution Medicines, Inc. (RVMD): The Biotech Stock with Biggest Upside Potential - Insider Monkey
Revolution Medicines’ SWOT analysis: stock poised for growth amid clinical trials - Investing.com Nigeria
Stocks Generating Improved Relative Strength: Revolution Medicines - MSN
Revolution Medicines (NASDAQ:RVMD) Stock Price Expected to Rise, UBS Group Analyst Says - Defense World
UBS Group Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) Stock - MarketBeat
Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Principal Financial Group Inc. Trims Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - Defense World
Brokerages Set Revolution Medicines, Inc. (NASDAQ:RVMD) Price Target at $65.82 - Defense World
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Revolution Medicines (RVMD) Shares Cross Below 200 DMA - Nasdaq
Revolution Medicines Becomes Oversold (RVMD) - Nasdaq
(RVMD) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Revolution Medicines divulges new GTPase KRAS, NRAS and HRAS inhibitors - BioWorld Online
Revolution Medicines COO Margaret Horn sells shares worth $196,553 - Investing.com India
Revolution Medicines CEO Mark Goldsmith sells $531,860 in stock By Investing.com - Investing.com Australia
Break Through Cancer and Revolution Medicines Collaborate to Study Biomarkers for RAS(ON) Inhibitor in - EIN News
Revolution Medicines CFO Jack Anders sells shares worth $119,639 By Investing.com - Investing.com Australia
Revolution Medicines general counsel sells $72,600 in stock - Investing.com India
Revolution Medicines CEO Mark Goldsmith sells $531,860 in stock - Investing.com India
Revolution Medicines COO Margaret Horn sells shares worth $196,553 By Investing.com - Investing.com Canada
Revolution Medicines, Inc. (NASDAQ:RVMD) COO Sells $196,536.60 in Stock - MarketBeat
Revolution Medicines CFO Jack Anders sells shares worth $119,639 - Investing.com
Insider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) Insider Sells 11,714 Shares of Stock - MarketBeat
Jack Anders Sells 2,635 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) Stock - MarketBeat
Finance Watch: FOPO Surge Continues With Big Offerings From Revolution, NewAmsterdam - Citeline News & Insights
(RVMD) Technical Data - Stock Traders Daily
Revolution Medicines' SWOT analysis: RAS inhibitor stock shows promise amid clinical trials - Investing.com
Wilmington Savings Fund Society FSB Invests $801,000 in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Barclays PLC Buys 192,021 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
One Revolution Medicines Insider Raised Their Stake In The Previous Year - Yahoo Finance
State Street Corp Has $239.43 Million Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Verition Fund Management LLC Takes Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines (NASDAQ:RVMD) Shares Gap Up on Insider Buying Activity - Defense World
Revolution Medicines director Schroeder acquires $59.9m in stock By Investing.com - Investing.com Australia
Revolution Medicines director Schroeder acquires $59.9m in stock - Investing.com India
Revolution Medicines Inc (RVMD) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):